Subscribe

Pomalidomide a Promising New Immunomodulatory Drug for Multiple Myeloma

February 2012 Vol 5, No 1, Special Issue - Multiple Myeloma, Multiple Myeloma, Multiple Myeloma

Early-phase studies of the new immunomodulatory drug poma­lidomide drew considerable interest at ASH 2011 and generated enthusiasm from myeloma specialists.

Paul G. Richardson, MD, of Dana-Farber Cancer Institute, Boston, who has led trials of pomalidomide, commented, “Over 40% clinical benefit rate and almost 17 months median survival in heavily pretreated patients is fantastic.”

A phase 2 study compared pomalidomide alone versus pomalidomide plus low-dose dexamethasone in 221 patients with relapsed/refractory disease. Patients had received an average of 5 previous lines of therapy, and most of them had progressed with bortez­omib or with lenalidomide therapy.

Pomalidomide plus dexamethasone led to a partial response in 34% of patients compared with 13% of patients responding to pomalidomide alone; another 11% of patients had minor responses to the combination regimen.

Median progression-free survival rates were 4.7 months with the combination and 2.7 months with pomalidomide alone, and median overall survival (OS) rates were 16.9 months and 14 months, respectively.

Similar findings emerged from the French phase 2 IFM 2009-02 study of pomalidomide plus low-dose dexa­methasone in 84 patients with disease refractory to both lenalidomide and bortezomib.

Responses with the combination were observed in 34.5% of patients, and stable disease was present in 48% of patients. Median time to progression was 9.1 months, and median OS was 13.4 months, according to Xavier Leleu, MD, PhD, of Hôpital Claude Huriez, CHRU, Lille, France.

Pomalidomide Plus 2 Drugs and Maintenance
Italian investigators combined pomalidomide with 2 other agents, cyclophosphamide and prednisone, followed by maintenance with pomalidomide plus cyclophosphamide in a phase 2 study of 29 relapsed/refractory patients.

After a median of 4 cycles, partial response or better was observed in 81% of the patients with refractory disease and in 55.5% of the patients who relapsed. Very good partial response or better was seen in 27% and 28% of patients, respectively, and complete responses were documented in 9% and 5.5% of patients, respectively, according to Antonio Palumbo, MD, of the University of Torino in Italy, for the Italian Multiple Myeloma Network.

Dr Palumbo also suggested that using a combination with “a good risk-benefit ratio, where there is not much toxicity,” and continuing the 3 drugs as maintenance therapy, “may help explain the higher proportion of responses” in this study.

Pomalidomide was generally well tolerated in all studies. The most common grade 3 or 4 toxicities were neutropenia, anemia, pneumonia, thrombocytopenia, and fatigue. More unusual grade 3 or 4 nonhematologic toxicities include rash and central neurologic toxicity in <10% of pa­tients. Phase 3 trials are currently evaluating pomalidomide in various drug combinations.—CH

Related Items
Novel BCMA-Directed CAR T-Cell Therapy Had Excellent Responses in Heavily Pretreated Patients with Multiple Myeloma
Phoebe Starr
February 2020 Vol 13, Special Issue published on February 25, 2020 in Multiple Myeloma
Dual-Targeted CAR T-Cell Therapy Leads to Very High Response Rates in Relapsed or Refractory Multiple Myeloma
Phoebe Starr
February 2020 Vol 13, Special Issue published on February 25, 2020 in Multiple Myeloma
Vincristine, Racial Disparities in Multiple Myeloma, and HER2 Metastatic Breast Cancer Are in the News
Yvette Florio Lane
Web Exclusives published on October 22, 2019 in Breast Cancer, FDA Approvals, In the News, Multiple Myeloma, Pediatric Cancer
FDA Approves Darzalex Combination for First-Line Treatment of Transplant-Eligible Patients with Multiple Myeloma
Web Exclusives published on September 27, 2019 in FDA Approvals, Multiple Myeloma, In the News
Elotuzumab, Lenalidomide, and Dexamethasone Combination Demonstrates High Response Rate in High-Risk Smoldering Multiple Myeloma
Chase Doyle
January/February 2019, Vol 12, Special Issue: Payers’ Perspectives in Oncology: ASH 2018 Highlights published on February 27, 2019 in Multiple Myeloma
Last modified: March 16, 2012
Copyright © Engage Healthcare Communications, LLC. All rights reserved.